­
­
­
­

Inventi Impact - Dermatology
(Formerly Inventi Rapid/Impact: Derma)

Articles

  • Inventi:hdr/92/14
    CLINICAL PRESENTATION, PATHOGENESIS, DIAGNOSIS AND TREATMENT OF EPIDERMOLYSIS BULLOSA ACQUISITA
    Ralf J Ludwig

    Epidermolysis bullosa acquisita (EBA) is a chronic mucocutaneous autoimmune skin blistering disease.The pathogenic relevance of autoantibodies targeting type VII collagen (COL7) has been well-documented. Therefore, EBA is a prototypical autoimmune disease with a well-characterized pathogenic relevance of autoantibody binding to the target antigen. EBA is a rare disease with an incidence of 0.2 new cases per million and per year. The current treatment of EBA relies on general immunosuppressive therapy, which does not lead to remission in all cases. Therefore, there is a high, so far unmet medical need for the development of novel therapeutic options. During the last 10 years, several novel in vitro and in vivo models of EBA have been established. These models demonstrated a critical role of the genetic background, T cells, and cytokines for mediating the loss of tolerance towards COL7. Neutrophils, complement activation, Fc gammareceptor engagement, cytokines, severalmolecules involved in cell signaling, release of reactive oxygen species, and matrix metalloproteinases are crucial for autoantibody-induced tissue injury in EBA. Based on this growing understanding of the diseases’ pathogenesis, several potential novel therapeutic targets have emerged. In this review, the clinical presentation, pathogenesis, diagnosis, and current treatment options for EBA are discussed in detail.

    How to Cite this Article
    CC Compliant Citation: Ralf J. Ludwig, “Clinical Presentation, Pathogenesis, Diagnosis, and Treatment of Epidermolysis Bullosa Acquisita,” ISRN Dermatology, vol. 2013, Article ID 812029, 25 pages, 2013. doi:10.1155/2013/812029.
    Download Full Text